2. Search Result
Search Result
Pathways Recommended: PI3K/Akt/mTOR
Results for "

SOX5/PI3K/AKT

" in MedChemExpress (MCE) Product Catalog:

2082

Inhibitors & Agonists

13

Screening Libraries

5

Fluorescent Dyes

28

Biochemical Assay Reagents

66

Peptides

37

Inhibitory Antibodies

499

Natural
Products

19

Recombinant Proteins

90

Isotope-Labeled Compounds

59

Antibodies

7

Click Chemistry

29

Oligonucleotides

4

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-144806
    PI3K/AKT-IN-1
    10+ Cited Publications

    		 PI3K Akt Apoptosis Cancer
    PI3K/AKT-IN-1 is an effective PI3K/AKT dual inhibitor (IC50 of 6.99, 4.01 and 3.36 μM for PI3Kγ, PI3Kδ and AKT, respectively). PI3K/AKT-IN-1 has anticancer activity and acts by inhibiting PI3K/AKT axis and inducing caspase 3 dependent apoptosis .
    PI3K/AKT-IN-1
  • HY-146751
    PI3K/Akt/mTOR-IN-2
    4 Publications Verification

    		 PI3K Akt mTOR Apoptosis Cancer
    PI3K/Akt/mTOR-IN-2 is a PI3K/AKT/mTOR pathway inhibitor. PI3K/Akt/mTOR-IN-2 possess anti-cancer effects and selectivity against MDA-MB-231 cells with IC50 value of 2.29 μM. PI3K/Akt/mTOR-IN-2 can induce cancer cell cycle arrest and apoptosis .
    PI3K/Akt/mTOR-IN-2
  • HY-151527
    PI3K/Akt/CREB activator 1
    4 Publications Verification

    		 Akt PI3K Epigenetic Reader Domain Neurological Disease
    PI3K/Akt/CREB activator 1 (compound AE-18) is a potent, orally active PI3K/Akt/CREB activator. PI3K/Akt/CREB activator 1 promotes neuronal proliferation, induced differentiation of Neuro-2a cells into a neuron-like morphology, and accelerated the establishment of axon-dendrite polarization of primary hippocampal neurons through upregulating brain-derived neurotrophic factor via the PI3K/Akt/CREB pathway. PI3K/Akt/CREB activator 1 can be used in research of vascular dementia (VaD) .
    PI3K/Akt/CREB activator 1
  • HY-12068
    PI3K-IN-1
    10+ Cited Publications

    XL-147 derivative 1

    		 PI3K Cancer
    PI3K-IN-1 (XL-147 derivative 1) is a potent inhibitor of PI3K. PI3K-IN-1 (25 μM) blocks PI3K/Akt signaling pathways .
    PI3K-IN-1
  • HY-111508
    PI3K/mTOR Inhibitor-2
    1 Publications Verification

    		 PI3K mTOR Cancer
    PI3K/mTOR Inhibitor-2 is a potent dual pan-PI3K/mTOR inhibitor with IC50s of 3.4/34/16/1 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ and 4.7 nM for mTOR . Antitumor activity .
    PI3K/mTOR Inhibitor-2
  • HY-14971
    (E)-Akt inhibitor-IV
    3 Publications Verification

    (E)-AKTIV

    		 Akt Cancer
    (E)-Akt inhibitor-IV ((E)-AKTIV) is a PI3K-Akt inhibitor, with potent cytotoxic .
    (E)-Akt inhibitor-IV
  • HY-151622
    PI3K/mTOR Inhibitor-11
    2 Publications Verification

    		 PI3K mTOR Cancer
    PI3K/mTOR Inhibitor-11 is an orally active PI3K/mTOR inhibitor (IC50: 3.5, 4.6, and 21.3 nM for PI3Kα, PI3Kδ, and mTOR). PI3K/mTOR Inhibitor-11 regulates the PI3K/AKT/mTOR signaling pathway by inhibiting the phosphorylation of AKT and S6 proteins. PI3K/mTOR Inhibitor-11 can be used in the research of cancers .
    PI3K/mTOR Inhibitor-11
  • HY-143404
    PI3K-IN-30
    3 Publications Verification

    		 PI3K Cancer
    PI3K-IN-30 (compound 6d) is a potent PI3K inhibitor with IC50s of 5.1, 136, 30.7 and 8.9 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively .
    PI3K-IN-30
  • HY-RS20822
    Sox5 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Sox5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sox5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Sox5 Mouse Pre-designed siRNA Set A
    Sox5 Mouse Pre-designed siRNA Set A
  • HY-10620
    PI3K-IN-22

    		PI3K mTOR Cancer
    PI3K-IN-22 is a PI3Kα/mTOR dual kinase inhibitor. PI3K-IN-22 has IC50s of 0.9, 0.6 nM for PI3Kα and mTOR, respectively. PI3K-IN-22 can be used for the research of cancer .
    PI3K-IN-22
  • HY-128333
    PI3K/mTOR Inhibitor-4

    		PI3K mTOR Cancer
    PI3K/mTOR Inhibitor-4 is an orally active pan-class I PI3K/mTOR inhibitor. PI3K/mTOR Inhibitor-4 has enzymatic inhibition activity for PI3Kα, PI3Kγ, PI3Kδ and mTOR with IC50 values of 0.63 nM, 22 nM, 9.2 nM and 13.85 nM, respectively. PI3K/mTOR Inhibitor-4 can be used for the research of cancer .
    PI3K/mTOR Inhibitor-4
  • HY-153120A
    PI3K/mTOR Inhibitor-13 sodium

    		PI3K mTOR Cancer
    PI3K/mTOR Inhibitor-13 sodium is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and mTOR kinase. PI3K/mTOR Inhibitor-13 sodium has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .
    PI3K/mTOR Inhibitor-13 sodium
  • HY-147284
    PI3K-IN-37

    		PI3K mTOR Others
    PI3K-IN-37 (Example 84.1) is a PI3K α/β/δ inhibitor with IC50s of 6, 8, 4 nM, respectively. PI3K-IN-37 can also inhibit mTOR (IC50=4 nM) .
    PI3K-IN-37
  • HY-147768
    PI3K/AKT-IN-2

    		PI3K Akt Microtubule/Tubulin MMP Apoptosis Cancer
    PI3K/AKT-IN-2 (Compound 12c) is a PI3K and AKT inhibitor. PI3K/AKT-IN-2 blocks the epithelial-mesenchymal transition (EMT) and induces apoptosis. PI3K/AKT-IN-2 inhibits the polymerization of tubulin .
    PI3K/AKT-IN-2
  • HY-176854
    PI3K/mTOR-IN-18

    		PI3K mTOR Cancer
    PI3K/mTOR-IN-18 (Compound 12) is a highly selective dual PI3K/mTOR inhibitor. PI3K/mTOR-IN-18 shows antitumor effects via competitive binding to PI3Kα (Ki=0.130 nM) and mTOR (Ki=0.111 nM). PI3K/mTOR-IN-18 blocks the PI3K/AKT/mTOR pathway and inhibits tumor cell proliferation (IC50=144 nM). PI3K/mTOR-IN-18 is promising for research of solid tumors (e.g., breast, NSCLC) .
    PI3K/mTOR-IN-18
  • HY-RS13596
    SOX5 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    SOX5 Human Pre-designed siRNA Set A contains three designed siRNAs for SOX5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SOX5 Human Pre-designed siRNA Set A
    SOX5 Human Pre-designed siRNA Set A
  • HY-109633
    PI3K/mTOR-IN-23

    		mTOR PI3K Cancer
    PI3K/mTOR-IN-23 is a dual inhibitor of PI3K and mTOR with IC50 values of 49 and 41 nM. PI3K/mTOR-IN-23 inhibits cancer cells proliferation .
    PI3K/mTOR-IN-23
  • HY-143403
    PI3K-IN-31

    		PI3K Cancer
    PI3K-IN-31 (Compound 6b) is a potent PI3K inhibitor with IC50s of 3.7 nM, 74 nM, 14.6 nM, and 9.9 nM for PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, respectively. PI3K-IN-31 has anticancer effects .
    PI3K-IN-31
  • HY-133124
    PARP/PI3K-IN-1

    		PARP PI3K Apoptosis Cancer
    PARP/PI3K-IN-1 (compound 15) is a potent PARP/PI3K inhibitor with pIC50 values of 8.22, 8.44, 8.25, 6.54, 8.13, 6.08 for PARP-1, PARP-2, PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ, respectively. PARP/PI3K-IN-1 is a highly effective anticancer compound targeted against a wide range of oncologic diseases .
    PARP/PI3K-IN-1
  • HY-142676
    PI3K-IN-26

    		PI3K Inflammation/Immunology Cancer
    PI3K-IN-26 is a potent PI3K inhibitor with an IC50 of 36 nM for SU-DHL-6 cells (WO2016066142A1, compound 1) .
    PI3K-IN-26
  • HY-179155
    PI3K/mTOR-IN-19

    		PI3K mTOR Apoptosis Bcl-2 Family MDM-2/p53 Telomerase Mitochondrial Metabolism Inflammation/Immunology Cancer
    PI3K/mTOR-IN-19 is an orally active, potent, selective PI3K (IC50 = 4.23 nM) and mTOR (IC50 = 2.3 nM) inhibitor. PI3K/mTOR-IN-19 significantly inhibits Eca109 cell viability and induces apoptosis. PI3K/mTOR-IN-19 causes G0/G1 cell cycle arrest, decreased mitochondrial membrane potential, and demonstrates marked telomerase inhibitory activity. PI3K/mTOR-IN-19 modulates the expression of key apoptotic regulators (Bcl-2, Bax, and p53) and downregulates the PI3K/Akt/mTOR signaling pathway. PI3K/mTOR-IN-19 can be used for the study of esophageal cancer .
    PI3K/mTOR-IN-19
  • HY-176421
    PROTAC PI3K/110β degrader-1

    		PROTACs PI3K Cancer
    PROTAC PI3K/110β degrader-1 (J-9) is a PROTAC based PI3K/110β degrader (Red: PI3K/110β inhibitor (HY-75124), black: linker, Blue: E3 ligase ligand) .
    PROTAC PI3K/110β degrader-1
  • HY-RS27336
    Sox5 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Sox5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sox5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Sox5 Rat Pre-designed siRNA Set A
    Sox5 Rat Pre-designed siRNA Set A
  • HY-142677
    PI3K-IN-27

    		PI3K Inflammation/Immunology Cancer
    PI3K-IN-27 is a potent inhibitor of PI3K. PI3K belongs to a large family of lipid signaling kinase that plays key role in cellular process including cell growth, differentiation, migration and apoptosis. PI3K-IN-27 has the potential for the research of hyper-proliferative diseases like cancer and inflammation, or immune and autoimmune diseases (extracted from patent WO2021233227A1, compound 1) .
    PI3K-IN-27
  • HY-112602
    PI3K/mTOR Inhibitor-1

    		PI3K mTOR Cancer
    PI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dual PI3K/mTOR inhibitor with IC50s of 20/376/204/46 nM and 186 nM for PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ and mTOR, respectively . Antitumor activity .
    PI3K/mTOR Inhibitor-1
  • HY-174469
    PROTAC PI3K/110β degrader-2

    		PROTACs P-glycoprotein Apoptosis Reactive Oxygen Species (ROS) Akt Bcl-2 Family Na+/K+ ATPase PI3K Cancer
    PROTAC PI3K/110β degrader-2 is a selective PI3K/p110β PROTAC degrader. PROTAC PI3K/110β degrader-2 can significantly degrade 110β protein and inhibit the expression of P-glycoprotein. PROTAC PI3K/110β degrader-2 can increase the level of reactive oxygen species (ROS). PROTAC PI3K/110β degrader-2 exerts anti-tumor effects by activating the endoplasmic reticulum stress (ERS)-mediated mitochondrial apoptosis pathway and inhibiting the AKT/Bcl-2 signaling pathway. PROTAC PI3K/110β degrader-2 can be used for research on cancer. (Pink: PI3K/110β Ligand (HY-75124); Blue: VHL Ligand (HY-125845); Black: Linker (HY-W002042)) .
    PROTAC PI3K/110β degrader-2
  • HY-162802
    PI3K/AKT-IN-4

    		Apoptosis PI3K Akt PARP CDK Cancer
    PI3K/AKT-IN-4 (compound 3) is a diterpenoid that can be isolated from the roots and rhizomes of Salvia castanea Dielsf. PI3K/AKT-IN-4 has antitumor activity, inhibiting cell viability and proliferation (IC50=4.72 μM) and promoting apoptosis by blocking the G0/G1 phase of the Hep3B cell cycle, inducing mitochondrial dysfunction and oxidative stress. In addition, PI3K/AKT-IN-4 inhibits hepatocellular carcinoma by inhibiting the PI3K-Akt signaling pathway and binding to PARP1 and CDK2 targets .
    PI3K/AKT-IN-4
  • HY-121684
    Ramentaceone

    7-Methyljuglon

    		 PI3K Apoptosis Cancer
    Ramentaceone (7-Methyljuglon), a naphthoquinone that can be isolated from Drosera sp., inhibits PI3K activity. Ramentaceone (7-Methyljuglon) reduces the expression of the PI3K protein and inhibits the phosphorylation of the Akt protein in breast cancer cells. Ramentaceone (7-Methyljuglon) induces apoptosis .
    Ramentaceone
  • HY-109633A
    PI3K/mTOR-IN-23 dihydrochloride

    		mTOR PI3K Cancer
    PI3K/mTOR-IN-23 dihydrochloride is a dual inhibitor of PI3K and mTOR with IC50 values of 49 and 41 nM. PI3K/mTOR-IN-23 dihydrochloride inhibits cancer cells proliferation .
    PI3K/mTOR-IN-23 dihydrochloride
  • HY-150309
    PI3K-IN-54

    		PI3K Cancer
    PI3K-IN-54 (compound 10w) is a pan-PI3K inhibitor. The IC50 values of PI3K-IN-54 for p110α, p110β, and p110δ are 0.22 nM, 1.4 nM, and 0.38 nM, respectively. PI3K-IN-54 can be used in cancer research .
    PI3K-IN-54
  • HY-171558
    PI3K-IN-56

    		PI3K Akt Cancer
    PI3K-IN-56 (Compound 1) is an orally active, potent and selective irreversible inhibitor of phosphoinositide 3-kinase (PI3K). PI3K-IN-56 irreversibly blocks the phosphatidylinositol-3,4,5-triphosphate (PIP3) production and downstream AKT signaling pathway. PI3K-IN-56 is promising for research of PI3Kα-driven cancers, such as breast and ovarian cancers .
    PI3K-IN-56
  • HY-161816
    PI3K/AKT-IN-3

    		Apoptosis Autophagy PI3K Akt Cancer
    PI3K/AKT-IN-3 (compound 8C) can induce autophagy and apoptosis by inhibiting the PI3K/AKT signaling pathway. PI3K/AKT-IN-3 can be used in cancer research .
    PI3K/AKT-IN-3
  • HY-178993
    PI3K/AKT-IN-5

    		PI3K Akt Apoptosis Cancer
    PI3K/AKT-IN-5 (Compound 3h) is a PI3K/AKT inhibitor. PI3K/AKT-IN-5 exhibits outstanding broad-spectrum anti-cancer activity, especially being sensitive to colorectal cancer. PI3K/AKT-IN-5 significantly reduces cell colony formation, induces G2/M phase cell cycle arrest and cell apoptosis. PI3K/AKT-IN-5 can be used for research on colorectal cancer .
    PI3K/AKT-IN-5
  • HY-163511
    PI3K/Akt/mTOR-IN-4

    		Akt Apoptosis mTOR PI3K Microtubule/Tubulin Cancer
    PI3K/Akt/mTOR-IN-4 (compound 4r) is a potent PI3K/Akt/mTOR and tubulin polymerization inhibitor. PI3K/Akt/mTOR-IN-4 induce apoptosis and cell cycle arrest at G2/M phase. PI3K/Akt/mTOR-IN-4 decreases the expression of p-PI3K, p-Akt, and p-mTOR, β-tubulin .
    PI3K/Akt/mTOR-IN-4
  • HY-173007
    ALK/PI3K/AKT-IN-1

    		Akt PI3K Anaplastic lymphoma kinase (ALK) CDK Apoptosis Mitochondrial Metabolism Cancer
    ALK/PI3K/AKT-IN-1 (Compound 45) inhibits the proliferation of cancer cell A549, H1975 and PC9 with an IC50 of 0.44, 0.83 and 1.51 μM. ALK/PI3K/AKT-IN-1 increases the expression of p21 and p27, inhibits the activity of CDK2 and p-Rb, arrests the cell cycle at G1 phase. ALK/PI3K/AKT-IN-1 inhibits the ALK/PI3K/AKT signaling pathway, promotes the depolarization of mitochondrial membrane potential, and inducing apoptosis in A549 cell. ALK/PI3K/AKT-IN-1 inhibits the formation and growth of A549 cell spheroids .
    ALK/PI3K/AKT-IN-1
  • HY-147913
    PI3K/Akt/mTOR-IN-3

    		PI3K Akt mTOR Apoptosis Cancer
    PI3K/Akt/mTOR-IN-3 (compound 3d) is a potent PI3K/AKT/mTOR inhibitor. PI3K/Akt/mTOR-IN-3 displays the inhibitory activity in MCF-7, HeLa and HepG2 cells, with IC50 values of 0.77, 1.23, and 4.57μM, respectively. PI3K/Akt/mTOR-IN-3 inhibits the migration of MCF-7 and HeLa cells at the concentration of 4 μM. PI3K/Akt/mTOR-IN-3 induces cell apoptosis and S phase arrest .
    PI3K/Akt/mTOR-IN-3
  • HY-159517
    PI3K/Akt/mTOR-IN-5

    		Apoptosis PI3K Akt mTOR STAT Cancer
    PI3K/Akt/mTOR-IN-5 (compound D3) is a derivative of Pseudolaric Acid B (HY-N6939) with anti-tumor activity. PI3K/Akt/mTOR-IN-5 inhibits excessive proliferation of tumor cells through the PI3K/AKT/mTOR and STAT3/GPX4 pathways. PI3K/Akt/mTOR-IN-5 effectively inhibits EDU positivity, reduces colony formation, places HCT-116 cells in the S phase and G2/M phase, and induces apoptosis .
    PI3K/Akt/mTOR-IN-5
  • HY-156080
    PI3K-IN-48

    		PI3K Akt Cancer
    PI3K-IN-48 is a PI3K inhibitor with IC50 value of 1.55 ± 0.18 μM for A549 cells. PI3K-IN-48 can induce G0/G1 phase arrest, cell apoptosis, and down-regulate expression of p-PI3K and p-Akt. PI3K-IN-48 can be used for human lung cancers diseases research .
    PI3K-IN-48
  • HY-136806
    PI3K-IN-12

    		PI3K Cancer
    PI3K-IN-12 (comp 76) is a PI3K inhibitor .
    PI3K-IN-12
  • HY-147614
    PI3K/mTOR Inhibitor-7

    		PI3K mTOR Cancer
    PI3K/mTOR Inhibitor-7 (Compound 19i) is a potent and dual inhibitor of PI3K/mTOR. PI3K/mTOR Inhibitor-7 shows 4.7-fold higher potency than the positive control gedatolisib (0.3 vs. 1.4 μM, IC50 values). PI3K/mTOR Inhibitor-7 significantly suppresses the PI3K/Akt/mTOR signaling pathway at 10 μM. PI3K/mTOR Inhibitor-7 has the potential for the research of cancer diseases .
    PI3K/mTOR Inhibitor-7
  • HY-147613
    PI3K/mTOR Inhibitor-6

    		PI3K mTOR Cancer
    PI3K/mTOR Inhibitor-6 (Compound 19c) is a potent and dual inhibitor of PI3K/mTOR. PI3K/mTOR Inhibitor-6 displays better stability in artificial gastric fluids than gedatolisib. PI3K/mTOR Inhibitor-6 significantly suppresses the PI3K/Akt/mTOR signaling pathway at 10 μM. PI3K/mTOR Inhibitor-6 has the potential for the research of cancer diseases .
    PI3K/mTOR Inhibitor-6
  • HY-147898
    PI3K-IN-33

    		PI3K Apoptosis Cancer
    PI3K-IN-33 (Compound 6e) is a highly selective PI3K inhibitor with IC50 values of 11.73, 6.09 and 11.18 μM for PI3K-α、PI3K-β and PI3K-δ , respectively. PI3K-IN-33 arrests cell cycle at G2/M phase and induces apoptosis. PI3K-IN-33 can be used in leukemia research .
    PI3K-IN-33
  • HY-147900
    PI3K-IN-35

    		PI3K Apoptosis Cancer
    PI3K-IN-35 (Compound 6l) is a highly selective PI3K inhibitor with IC50 values of 13.98, 7.22 and 10.94 μM for PI3K-α、PI3K-β and PI3K-δ, respectively. PI3K-IN-35 arrests cell cycle at G2/M phase and induces apoptosis. PI3K-IN-35 can be used in leukemia research .
    PI3K-IN-35
  • HY-147899
    PI3K-IN-34

    		PI3K Apoptosis Cancer
    PI3K-IN-34 (Compound 6g) is a highly selective PI3K inhibitor with IC50 values of 11.73, 6.09 and 11.18 μM for PI3K-α、PI3K-β and PI3K-δ , respectively. PI3K-IN-34 arrests cell cycle at G2/M phase and induces apoptosis. PI3K-IN-34 can be used in leukemia research .
    PI3K-IN-34
  • HY-160282
    PI3K-IN-49

    		PI3K Cancer
    PI3K-IN-49 is a potent PI3K inhibitor. PI3K-IN-49 shows antiproliferative activity for Avg T-47D and Avg SKBR3 cells (WO2023239710A1; example 29) .
    PI3K-IN-49
  • HY-157295
    PI3K/HDAC-IN-3

    		PI3K HDAC Cancer
    PI3K/HDAC-IN-3 (36) is a PI3K and HDAC dual inhibitor, with IC50 values of 0.23 nM and 172 nM for PI3Kα and HDAC1, respectively. PI3K/HDAC-IN-3 (36) suppresses AKT phosphorylation and increased H3 acetylation in MV4-11 cells. PI3K/HDAC-IN-3 (36) exhibits significant and dose-dependent anticancer efficacy in a MV4-11 xenograft model .
    PI3K/HDAC-IN-3
  • HY-103030
    PI3K-IN-32

    		PI3K Cancer
    PI3K-IN-32 is an imidazopyridine derivative with a 3-NH2 substituent, and also a PI3K p110α inhibitor. PI3K-IN-32 is applicable for cancer research .
    PI3K-IN-32
  • HY-144450
    PI3K-IN-29

    		PI3K Akt Cancer
    PI3K-IN-29 is a potent PI3K inhibitor. PI3K-IN-29 displays good inhibition potencies against U87MG, HeLa and HL60 cells with IC50 values of 0.264, 2.04 and 1.14 µM, respectively. PI3K-IN-29 inhibits PI3K/Akt pathway by inhibiting phosphorylation of Akt that is catalyzed by PI3K .
    PI3K-IN-29
  • HY-121672
    PI3K-IN-7

    		PI3K Akt Apoptosis Cancer
    PI3K-IN-7 (Compound C96) is a PI3K inhibitor. PI3K-IN-7 inhibits phosphorylation of AKT and the activation of an AKT downstream protein. PI3K-IN-7 induces apoptosis of the tumor cells. PI3K-IN-7 has low toxicity for normal cells. PI3K-IN-7 can be used for research of acute and chronic leukemia, multiple myeloma, lymphoma .
    PI3K-IN-7
  • HY-145432
    PI3K-IN-28

    		PI3K Cancer
    PI3K-IN-28 (Compound 6c) is a potent inhibitor of PI3K. PI3K-IN-28 displays the most potent activity with lower toxic effects on MCF-10a. PI3K-IN-28 displays half-maximal inhibitory concentration (IC50, μM) values of 5.8, 2.3, and 7.9. PI3K-IN-28 is the most potent one with a selectivity index (SI) of 39 and is considered as a latent lead for further optimization of anticancer agents .
    PI3K-IN-28

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: